May 2016, Volume 2, Issue 5

May 2016

Volume 2, Issue 5

This issue features highlights from the 2016 ASH Annual Meeting, a look at the dangers of predatory publishing, and more.

Table of Contents

May 2016

How long should a multiple myeloma patient receive lenalidomide maintenance therapy?

Sunday, May 1st, 2016
Here's how readers responded to a You Make the Call question about lenalidomide maintenance in a patient with multiple myeloma. Disclaimer: ASH does not recommend...

Kindred Spirits

Sunday, May 1st, 2016
“Kindred spirits are not so scarce as I used to think. It’s splendid to find out there are so many of them in the...

More Reasons to Become a Hematologist…

Sunday, May 1st, 2016
In last month’s Editor’s Corner, Keith Stewart, MBChB, MBA, asked readers why they chose to join the ranks of the International Society of Bloody...

May 2016

Health Volunteers Overseas and ASH Expand Their Reach

Sunday, May 1st, 2016
Volunteer Your Hematology Expertise in Peru Health Volunteers Overseas and ASH expand their reach with new program site In partnership with Health Volunteers Overseas (HVO), ASH...

Remembering Yvette Fay Francis-McBarnette, and more

Sunday, May 1st, 2016
Yvette Fay Francis-McBarnette, MD (1926–2016) Yvette Fay Francis-McBarnette, MD, a pioneer in treating children with sickle cell anemia, died on March 28, 2016, at the...

May 2016

Dr. Schrier in his wine cellar

Through the Grapevine: Stanley L. Schrier, MD

Sunday, May 1st, 2016
When did you become interested in wine and producing your own wines? My interest in wine started in the late 1960s, when I began drinking...

Pulling Back the Curtain: Ranjana Advani, MD

Sunday, May 1st, 2016
When did you know that you wanted to pursue medicine as a career? My parents told me that I wanted to be a doctor like...
Robert Negrin

If You Build It, They Will Come: Robert Negrin Shares His Vision for Blood...

Sunday, May 1st, 2016
When Robert Negrin, MD, was growing up in Silver Spring, Maryland, if someone had told his parents that their son would one day become...

Attack of the Data Suckers!

Sunday, May 1st, 2016
A warning against “research parasites” may open the door to better data sharing. It all started with an editorial published by the editors of The...

Healing Mind, Body, and Soul

Sunday, May 1st, 2016
Given the nature of medicine, it is natural to assume that humanism would be a central, highly regarded component. Many people in health care,...

CMS Expands Coverage for Hematopoietic Cell Transplantation: Proceed with Cautious Optimism

Sunday, May 1st, 2016
The recent decision by the Centers for Medicare and Medicaid Services (CMS) to cover allogeneic hematopoietic cell transplantation (alloHCT) for eligible patients with sickle...

May 2016

Understanding Transplant in Lymphoma

Sunday, May 1st, 2016
Hematopoietic cell transplantation (HCT), also called stem cell or bone marrow transplantation, is a treatment option for patients with blood cancers such as leukemia,...

How I Teach Quality

Sunday, May 1st, 2016
In this edition, Colleen Morton, MBBCh, MS, talks about teaching quality improvement. Dr. Morton will also be discussing quality improvement in the changing U.S. health-care...

How long should a multiple myeloma patient receive lenalidomide maintenance therapy?

Sunday, May 1st, 2016
This month, Sagar Lonial, MD, addresses a question about duration of maintenance therapy in a patient diagnosed with multiple myeloma.I have a young patient...

May 2016

Thrombocytopenia and Sepsis: A Life-Threatening Combination

Sunday, May 1st, 2016
Patients with thrombocytopenia who are admitted to the intensive care unit (ICU) with sepsis are at an increased risk of mortality, compared with patients...

FDA Grants Orphan Designation to Iomab-B for Older Patients With AML

Sunday, May 1st, 2016
The U.S. FDA granted orphan drug designation to Iomab-B for the treatment of relapsed/refractory acute myeloid leukemia (AML) prior to hematopoietic cell transplantation in...

IMWG Updates Myeloma-Related Renal Impairment Management Recommendations

Sunday, May 1st, 2016
The International Myeloma Working Group (IMWG) has updated its recommendations for the diagnosis and management of myeloma-related renal impairment. According to the new document,...

FDA Approves New Genetic Therapy for Hemophilia A

Sunday, May 1st, 2016
The U.S. FDA approved Kovaltry™ antihemophilic factor (recombinant), an unmodified, full-length factor VIII compound, for the treatment of hemophilia A in children and adults....

FDA Approves New Formulation of Melphalan

Sunday, May 1st, 2016
The U.S. FDA approved a new formulation of melphalan injection for use as a high-dose conditioning treatment prior to hematopoietic cell transplantation in multiple...

CDC Issues New Guidelines Aimed at Reducing Opioid Addiction Risk

Sunday, May 1st, 2016
The Centers for Disease Control and Prevention (CDC) released updated guidelines for prescribing opioids for chronic pain (outside of active cancer and palliative and...

FDA Approves Ibrutinib as Front-Line Therapy in CLL

Sunday, May 1st, 2016
The U.S. FDA approved ibrutinib as a first-line treatment for patients with chronic lymphocytic leukemia (CLL). The approval was based on the results of...

FDA Approves First Coagulation Factor–Albumin Fusion Protein for Hemophilia B

Sunday, May 1st, 2016
The U.S. Food and Drug Administration (FDA) approved coagulation factor IX (recombinant), albumin fusion protein, also known as albutrepenonacog alfa, for use in children...
WIB_icon

Defibrotide in Patients with VOD/SOS and Multi-Organ Failure Following Transplant

Sunday, May 1st, 2016
Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is a potentially fatal complication of allogeneic or autologous hematopoietic cell transplantation (HCT), and is...

Ibrutinib Plus Bendamustine and Rituximab Yields Positive Results for Patients With CLL/SLL

Sunday, May 1st, 2016
Adding ibrutinib to a standard treatment regimen of bendamustine and rituximab for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)...

Does CAR T-Cell Therapy Induce Remission Following AlloHCT in Patients With B-Cell Malignancies?

Sunday, May 1st, 2016
While allogeneic hematopoietic cell transplantation (alloHCT) is used in patients with advanced B-cell malignancies, it is not universally effective, and many relapse afterward. Donor...

Researchers Develop ELISA Assay to Rapidly Diagnose Variant von Willebrand Disease

Sunday, May 1st, 2016
Using a novel ELISA-based screening assay, researchers were able to correctly identify variant von Willebrand disease (vWD) phenotypes with 88 percent accuracy, according to...

Long-Term Follow-Up Confirms Benefit of High-Dose Daunorubicin Across Molecular and Cytogenetic Groups of AML...

Sunday, May 1st, 2016
In a long-term follow-up of the Eastern Cooperative Oncology Group−American College of Radiology Imaging Network Cancer Research Group (ECOG-ACRIN) E1900 study, researchers found that...

CMS Tests New Medicare Part B Reimbursement Model: How Will It Affect Hematologists?

Sunday, May 1st, 2016
In March, the Centers for Medicare & Medicaid Services (CMS) announced a proposed rule to test new models to improve Medicare Part B physician...

Novel DNA/RNA Genomic Profiling Assay Identifies Broad Range of Genomic Alterations in Hematologic Malignancies

Sunday, May 1st, 2016
Researchers have developed a novel, next-generation sequencing-based assay that successfully characterized genomic alterations in 93 percent of patients with hematologic malignancies. This genomic-profiling approach...

Long-Term Exposure to Low-Molecular-Weight Heparins May Put Patients at Risk for Bone Fractures

Sunday, May 1st, 2016
In men and non-pregnant women requiring at least three months of anticoagulation therapy, three- to six-months’ use of low-molecular-weight heparin (LMWH) may not increase...

What To Call What We Treat, Part I: WHO Releases Updated Classification of Lymphoid...

Sunday, May 1st, 2016
After nearly a decade since its last iteration, the World Health Organization (WHO) has revised its 2008 classification of lymphoid neoplasms, updating the current...

Older Age Affects Outcomes More Than Intensifying Treatment in AML Patients

Sunday, May 1st, 2016
Among older patients with acute myeloid leukemia (AML), age impacts outcomes more than treatment intensity, according to the authors of a report published in...

Study Examines Impact of ADAMTS-13 and von Willebrand Factor on Predicting VTE in Cancer...

Sunday, May 1st, 2016
Patients with cancer are at high risk for developing venous thromboembolism (VTE), and the risk is much higher if the patient has higher von...

May 2016

Characterizing Patient-Reported Pain Management Strategies for Hemophilia

Sunday, May 1st, 2016
Patients with hemophilia have to manage both bleeding issues, and the consequent joint pain that follows recurrent hemarthrosis. Regional and national U.S. surveys have...

Women With Clotting Factor Deficiencies Have Similar Excess Bleeding Risk, Regardless of Factor Levels

Sunday, May 1st, 2016
Women who have or are carriers for factor VIII (FVIII) or factor IX (FIX) deficiency often report excessive bleeding, though it is unclear how...

Real-World Studies Report on the Use of Recombinant Porcine Factor VIII for Acquired Hemophilia...

Sunday, May 1st, 2016
Two retrospective studies presented at the Thrombosis and Hemostasis Societies of North America 2016 Summit provided real-world data on recombinant porcine factor VIII (rpFVIII)...

IOM Workshop Tackles Immunotherapy Development, Use Issues

Sunday, May 1st, 2016
Earlier this year, the Institute of Medicine’s (IOM’s) National Cancer Policy Forum (NCPF), the National Academies of Sciences, Engineering, and Medicine, and the Health...

SHARE